Inventor · disambiguated record
Julian Kenyon
Also filed as: KENYON JULIAN · KENYON JULIAN NORMAN
4 granted patents·4 pending applications·4 citations·filing 2010–2022
64Inventor score
Top patents by PatentIndex Score
8 records- 0168US9636359B2Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agentKENYON JULIAN NORMAN·Filed 2010·Granted May 2, 2017·3 cites·21 claims
- 0267US10350239B2Pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agentPROPANC PTY LTD·Filed 2017·Granted Jul 16, 2019·1 cites·15 claims
- 0367US2023137573A1Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction AgentPROPANC PTY LTD·Filed 2022·Application pending·0 cites
- 0453US2019388463A1Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction AgentPROPANC PTY LTD·Filed 2019·Application pending·0 cites
- 0551US2023089740A1Cancer treatmentPROPANC PTY LTD·Filed 2022·Application pending·0 cites
- 0649US12419938B2Proenzyme compositionPROPANC PTY LTD·Filed 2016·Granted Sep 23, 2025·0 cites·4 claims
- 0742US11376313B2Cancer treatmentPROPANC PTY LTD·Filed 2017·Granted Jul 5, 2022·0 cites·12 claims
- 0834US2019134166A1Composition of proenzymes for cancer treatmentPROPANC PTY LTD·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Julian Kenyon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →